Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors

Documenti analoghi

• Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
  di: Gian Paolo Fadini, et al.
  Pubblicazione: (2019-05-01)
• SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
  di: Bonora, Benedetta Maria, et al.
  Pubblicazione: (2021)
• Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
  di: Fadini, Gian Paolo, et al.
  Pubblicazione: (2018)
• Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
  di: Fadini, Gian Paolo, et al.
  Pubblicazione: (2018)
• Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
  di: Gatti, Milo, et al.
  Pubblicazione: (2021)